IMA Stock — ImageneBio Inc.: Cash, EV, Pipeline

Share price

$4.89

Market cap

$55.5M

Cash

$136.2M

Enterprise value

-$80.7M

Balance sheet

Cash	$136.2M
Debt	$0.0M
Net cash	$136.2M
Enterprise value	-$80.7M
Basic shares	16.2M shares
Fully diluted shares	14.0M shares
Fully diluted market cap	$68.2M
Cash per share	$8.41

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IMA daily closes…

Loading price history…

Pipeline assets

Olevaprubart

Phase 2 · Active Modality: non-depleting monoclonal antibody

Aliases IMG-007

Target OX40 receptor

Indications

Atopic dermatitis (AD) (Phase 2)
Alopecia areata (AA) (Phase 2)

Status note Multi-country Phase 2b dose-finding AD study began 2025; protocol amendment submitted to FDA and Health Canada for optimized dose exposure. Phase 1b/2a POC in severe AA completed (29 patients).

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	909,269	+530,713	0.10%	2026-08-14
RTW Investments	334,445	no change	0.02%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

IMA — ImageneBio Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders